Stocksigma LogoStocksigma Logo

Orchid Pharma Releases FY25-26 BRSR Highlighting Operational and Sustainability Metrics

Orchid Pharma reported FY25-26 standalone turnover of ₹1,23,277.84 lakh and net worth of ₹1,64,667.59 lakh, with Active Pharmaceutical Ingredients (APIs)

Orchid Pharma Releases FY25-26 BRSR Highlighting Operational and Sustainability Metrics

Orchid Pharma Ltd · Others (Uncategorized) · 08 Sept 2026, 9:32 pm

Orchid Pharma Releases FY25-26 BRSR Highlighting Operational and Sustainability Metrics Orchid Pharma reported FY25-26 standalone turnover of ₹1,23,277.84 lakh and net worth of ₹1,64,667.59 lakh, with Active Pharmaceutical Ingredients (APIs), primarily Cephalosporin, generating 97% of total revenue. Exports contributed 64.55% across 52 countries. Total energy consumption stood at 1,498.12 Joules, with renewable sources comprising 68% of electricity and wind/solar usage. Total Scope 1 and Scope 2 GHG emissions declined to 54,412.00 metric tonnes and 12,806.00 metric tonnes of CO2 equivalent, respectively. The company maintains a 100% Zero Liquid Discharge system across its operations.

Original exchange filing (PDF)

More announcements from Orchid Pharma Ltd

All Orchid Pharma Ltd announcements